3rd Annual Microbiome: Regulatory, Quality Developments and Commercialization Summit
16-17

October 2019

Germany

Berlin

About

We are pleased to invite you to the 3rd Annual Microbiome: Regulatory, Quality Developments and Commercialization Summit scheduled for October 16-17, 2019, in Berlin, Germany. This premier B2B event provides you with an appropriate platform to engage with and discuss ideas with your fellow peers while facilitating a professional atmosphere and environment for excellent company representation and development. The Summit will shed light on current challenges, best practices and inside views of the future of microbiome-based products in relation t...

We are pleased to invite you to the 3rd Annual Microbiome: Regulatory, Quality Developments and Commercialization Summit scheduled for October 16-17, 2019, in Berlin, Germany. This premier B2B event provides you with an appropriate platform to engage with and discuss ideas with your fellow peers while facilitating a professional atmosphere and environment for excellent company representation and development. The Summit will shed light on current challenges, best practices and inside views of the future of microbiome-based products in relation to quality, safety and efficiency. We will discuss key findings, critical insights and recommendations for driving efficient strategies within the microbiome landscape. It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Berlin in October!

more info
Who Should Attend

Chief Executives, Directors, Vice Presidents, Department Heads, Leaders and Managers specialising in:

  • Ageing
  • Alzheimer’s
  • Antimicrobials
  • Atherosclerosis
  • Autologous
  • Bacteriotherapy
  • Biofuels
  • Biology
  • Bioreactors
  • Bone Marrow Transplantation
  • Bulk Material
  • Cell Culture
  • Clinical Development
  • Clinical Trial
  • CMO
  • Commercialisation
  • Confocal Microscopy
  • Cytokines
  • Delivery
  • Drug Delivery
  • Ecology
  • Endocrinology
  • Faecal Microbiota
  • Filtration
  • FMT
  • Fusobacteria
  • Gastrointestinal
  • Genomics
  • GMP
  • Gut-Brain Axis
  • Hypertension
  • IBS
  • Immuno-Inflammation
  • In Vitro
  • IND
  • Inflammation
  • Invention
  • Isolation
  • LBPs
  • Lifesciences
  • Live Cell Therapeutics
  • Lyophiliser
  • Medicinal Chemistry
  • Metagenomic
  • Microbiology
  • Microbiota
  • Microganisms
  • Mucosal Immunology
  • NASH
  • Nutraceuticals
  • Nutrition
  • Oncoviruses
  • Pathogen
  • Phages
  • Prebiotics
  • Process Cultivation
  • Production
  • Quality Control
  • Regulatory
  • Sequencing
  • Small Molecule
  • Symbiosys
  • Synthetic Biology
  • Testing
  • Translational Sciences
  • Vaccines
  • Western Blotting
  • ALS
  • Analytical
  • Aseptic
  • Autoimmune
  • Bacteriology
  • Biochemistry
  • Bioinformatics
  • Biomarker
  • Biotechnology
  • Bowel Syndrome
  • Cell Biology
  • CGMP
  • Clinical Study
  • CMC
  • CNS
  • Computational Biology
  • Contract Manufacturing
  • Delivery
  • DNA
  • Dysbiosis
  • Eligobiotics
  • Epidemiology
  • Fermentation
  • Flow Cytometry
  • Freeze Drying
  • Gastroenterology
  • Genome Sequencing
  • GI
  • Gut
  • High Throughput Screening
  • IBD
  • ICH
  • Immuno-Oncology
  • In Vivo
  • Infectious Disease
  • Intellectual Property
  • Investment
  • Laboratory
  • Licensing
  • Live Biotherapeutics
  • Liver Disease
  • Manufacturing
  • Mergers & Acquisition
  • Metatranscriptomics
  • Microbiome
  • Microbiotherapy
  • Molecular Biology
  • Multiple Sclerosis
  • Neurodegenerative
  • Nutrients
  • Obesity
  • Patent
  • PCR
  • Pre-Clinical
  • Probiotics
  • Product Development
  • QA
  • R&D
  • Safety
  • Skin
  • SOP
  • Synbiotics
  • Technology Transfer
  • Tissue Culture
  • Ulcerative Colitis
  • Viruses
  • Yeast
Key Practical Learning Points of the Summit

Emerging tech and developments to bring to the market efficient and safe microbiome products
CMC strategies to successfully develop live biotherapeutic products (LBPs)
Regulatory perspective on probiotics, LBPs and FMTs
Critical considerations to design clinical trials for microbiome products
GMP manufacturing and scale up considerations related to LBPs
Commercialisation of microbiome-based diagnostics, therapies and service

Annual

Events

"